SCHEMBL337027

SCHEMBL337027

COC(=O)c1c(O)c2cc(N3CCCCC3)nnc2n(C)c1=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.39
KDM4E B2RXH2 6/20 0.34
NPC1 O15118 4/20 0.34
RAB9A P51151 3/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
NPSR1 Q6W5P4 1/20 0.34
MAPT P10636 5/20 0.34
TP53 P04637 2/20 0.34
POLB P06746 2/20 0.34
TDP1 Q9NUW8 1/20 0.34
HPGD P15428 1/20 0.33
ALOX12 P18054 1/20 0.33
CNR2 P34972 1/20 0.33
GAA P10253 1/20 0.33
PPARG P37231 1/20 0.33
NCOA2 Q15596 1/20 0.33
MEN1 O00255 1/20 0.33
USP2 O75604 1/20 0.33
PKM P14618 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL336475 0.82 EGLN1 (0.49)
SCHEMBL337571 0.80 CALCA (0.41) KDM4E
SCHEMBL336867 0.78 ALDH1A1 (0.41) ALDH1A1KDM4ENPC1RAB9ANPSR1
SCHEMBL336185 0.78 ALDH1A1 (0.40) ALDH1A1KDM4EMAPTHPGDCNR2
SCHEMBL2434416 0.70 ALDH1A1 (0.44) ALDH1A1KDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL2577076 0.67 ALDH1A1 (0.40) ALDH1A1KDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL2579380 0.67 ALDH1A1 (0.45) ALDH1A1KDM4EHPGD
SCHEMBL2578302 0.67 CNR2 (0.46) ALDH1A1KDM4ESMN1; SMN2MAPTCNR2
SCHEMBL10080871 0.67 ALDH1A1 (0.55) ALDH1A1KDM4ENPC1SMN1; SMN2MAPT
SCHEMBL2580133 0.65 EGLN1 (0.53)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097620-B2 Diazaquinolones that inhibit prolyl hydroxylase activity AMGEN INC. (US) 2012-01-17 US disclosed
EP-2155746-A2 DIAZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY Amgen, Inc (US) 2010-02-24 EP disclosed
US-20090099171-A1 Diazaquinolones that inhibit prolyl hydroxylase activity AMGEN INC. (US) 2009-04-16 US disclosed
WO-2008137084-A2 DIAZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY AMGEN INC. (US) 2008-11-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099171-A1 Diazaquinolones that inhibit prolyl hydroxylase activity EGLN3, EGLN2, HIF1AN ALDH1A1 108/4885KDM4E 248/4885NPC1 2072/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.